GameChangers: Dupilumab in COPD

GameChangers: Dupilumab in COPD

A new biologic agent, Dupilimab, may be a possible treatment for chronic obstructive pulmonary disorder. Join host, Geoff Wall, as he evaluates the use of dupilimab in COPD with Type 2 inflammation

THE GAMECHANGER: Type 2 inflammation is driven by eosinophils and IL-4, 5, and 11. It occurs in 20% of patients with COPD. Dupilimab was able to decrease COPD exacerbations by 50% and improve symptoms

Upon successful completion of this course, learners should be able to:
1. Discuss the different phenotypes of COPD and treatment options
2. Describe the BOREAS trial and the applicability to patients with COPD

Geoffrey C. Wall, PharmD, FCCP, BCPS, CG
Professor of Clinical Sciences
Drake University College of Pharmacy and Health Sciences

Dr. Wall is a member of the Janssen Speaker’s Bureau. All relevant financial relationships have been mitigated.  

Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Release Date: August 21, 2023
Planned Expiration Date: August 21, 2024

Copyright 2023, CEimpact. All Rights Reserved. Any reproduction of this course without express permission is strictly forbidden.  

Universal Activity Number (UAN): 0107-0000-23-288-H01-P
Application-based CPE Activity

CEImpact is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Obtain CPE credit by completing the course, followed by the exam and evaluation (if applicable). Once successfully completed, your course will appear in your Completed Courses tab. Access your CPE statement of credit at

¹CEImpact provides you with two (2) opportunities to complete the exam. The learner will not receive CPE credit after two failed attempts.

Additional information


0h 30m

Topic Designator

Disease State/Drug Therapy



ACPE Topic




Release Date






ACPE Number


This course is in our subscription.